Table 3.
Univariate and multivariate analysis of baseline predictors of recurrence-free survival.
| Features | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95%CI) | p Value 1 | HR (95%CI) | p Value 1 | |
| Sex (F vs. M) | 0.69 (0.46–1.05) | 0.091 | ||
| Age at HCC enrollment | 1.01 (0.99–1.04) | 0.207 | ||
| Etiology (viral vs. others) | 0.88 (0.57–1.35) | 0.560 | ||
| Diameter (≥5 cm vs. <5 cm) | 2.60 (1.67–4.07) | <0.001 | 2.36 (1.45–3.83) | 0.001 |
| Child-Pugh score (B–C vs. A) | 1.47 (0.94–2.29) | 0.092 | ||
| BCLC stage (A vs. 0) | 2.21 (1.24–3.96) | 0.008 | 2.41 (1.22–4.75) | 0.011 |
| HCC Grade (3 vs. 1–2) | 1.41 (0.84–2.38) | 0.032 | 1.65 (1.04–4.67) | 0.003 |
| PVT (yes vs. no) | 2.39 (1.54–3.71) | <0.001 | 1.55 (0.60–4.01) | 0.363 |
| Malignant PVT (yes vs. no) | 2.40 (1.48–3.88) | <0.001 | 1.69 (0.62–4.61) | 0.304 |
| Type of treatment (locoregional vs. surgical) | 1.41 (0.81–2.48) | 0.229 | ||
| AFP ≥ 20 ng/mL (vs. < 20 ng/mL) | 1.23 (0.84–1.79) | 0.283 | ||
| AFP ≥ 200 ng/mL (vs. < 200 ng/mL) | 1.04 (0.54–1.99) | 0.412 | ||
| AFP ≥ 400 ng/mL (vs. < 400 ng/mL) | 1.97 (1.03–2.17) | 0.104 | ||
| AFP ≥ 1000 ng/mL (vs. < 1000 ng/mL) | 1.82 (1.20–4.13) | 0.021 | 1.95 (1.04–3.68) | 0.038 |
1 Cox regression analysis; CI: confidence interval; AFP: alpha-fetoprotein; BCLC: Barcellona Clinic Liver Cancer; HCC: hepatocellular carcinoma; HR: hazard ratio; PVT: portal vein thrombosis.